Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 2

Современные подходы к безинтерфероновой противовирусной терапии хронического вирусного гепатита С
И.Г. Никитин

Список литературы

1. Никитин И.Г., Попович Л.Д., Потапчик Е.Г. Экономическое бремя хронического гепатита С в России. Эпидемиология и инфекционные болезни. Актуальные вопросы 2015;6:9-13.
2. Никитин И.Г., Чуланов В.П., Андреева К.В., Мурашко М.М. Актуальные вопросы организации медицинской помощи пациентам с хроническими вирусными гепатитами. Эпидемиология и инфекционные болезни. Актуальные вопросы 2016;1:4-11.
3. Никитин И.Г. Хронический вирусный гепатит С: клиника, диагностика, лечение: Дис. … докт. мед. наук. М., 2000. 245 с.
4. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. AASLD/IDSA HCV guidance panel. Recommendations for testing, managing, and treating of hepatitis C website. Published 2017. Available from: http://hcvguidlines.org/ Accessed 2021 Aug 05.
5. European Association for the Study of the Liver; Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: final update of the series. Journal of Hepatology 2020 Nov;73(5):1170-1218.
6. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July 2018. Geneva, Switzerland: World Health Organization; 2018. 86 p. Available from: http://who.int/news-room/fact-sheets/hepatitis-c Accessed 2021 Aug 05.
7. Mejer N, Fahnøe U, Galli A, Ramirez S, Weiland O, Benfield T, Bukh J. Mutations identified in the hepatitis C virus (HCV) polymerase of patient with chronic HCV treated with ribavirin cause resistance and affect viral replication fidelity. Antimicrobial Agents and Chemotherapy 2020 Nov;64(12):e01417-20.
8. Welzel T, Yang M, Sajeew G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D. Assessing patients preference for treatment decision for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infection. Advances in Therapy 2019 Sep;36(9):2475-86.
9. Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez FR, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8-weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. Journal of Hepatology 2020 Mar;72(3):441-9.
10. Lampertico P, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, Brown A, Persico M, Wick N, Porcalla A, Pangerl A, Crown E, Larsen L, Yu Y, Wedemeyer H. Real-world effectiveness and safety of glecaprevir/pibrentasvir for treatment of patients with chronic HCV-infection: a meta-analysis. Journal of Hepatology 2020 Jun;72(6):1112-21.
11. Drysdale K, Ntuli Y, Bestwick J, Gelson W, Agarwal K, Forton D, Mutimer D, Elsharkawy AM, Townley C, Mahomed F, Foster GR. English hepatitis C registry data show high response rates to directly acting anti-virals even if treatment is not compensated. Alimentary Pharmacology & Therapy 2020 Jul;52(1):168-81.
12. Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM, Solà R. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Journal of Hepatology 2004 May;40(5):823-30.
13. U.S. Food & Drug Administration. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines mavyret, zepatier, and vosevi in some patients with advanced liver disease. FDA Drug Safety Communications. 08-28-2019. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and Accessed 2021 Aug 05.

References

1. Nikitin IG, Popovich LD, Potapchik EG. Economic burden of chronic hepatitis C in Russia. Epidemiology and Infectious Diseases. Current Items 2015;6:9-13 (In Russian).
2. Nikitin IG, Chulanov VP, Andreyeva KV, Murashko MM. Topical aspects of organization of medical care for patients with chronic viral hepatitis. Epidemiology and Infectious Diseases. Current Items 2016;1:4-11 (In Russian).
3. Nikitin IG. Chronic viral hepatitis C: clinic, diagnosis, treatment [Dissertation for the degree of Doctor of Medical Sciences]. Moscow, 2000. 245 p. (In Russian).
4. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. AASLD/IDSA HCV guidance panel. Recommendations for testing, managing, and treating of hepatitis C website. Published 2017. Available from: http://hcvguidlines.org/ Accessed 2021 Aug 05.
5. European Association for the Study of the Liver; Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: final update of the series. Journal of Hepatology 2020 Nov;73(5):1170-1218.
6. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July 2018. Geneva, Switzerland: World Health Organization; 2018. 86 p. Available from: http://who.int/news-room/fact-sheets/hepatitis-c Accessed 2021 Aug 05.
7. Mejer N, Fahnøe U, Galli A, Ramirez S, Weiland O, Benfield T, Bukh J. Mutations identified in the hepatitis C virus (HCV) polymerase of patient with chronic HCV treated with ribavirin cause resistance and affect viral replication fidelity. Antimicrobial Agents and Chemotherapy 2020 Nov;64(12):e01417-20.
8. Welzel T, Yang M, Sajeew G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D. Assessing patients preference for treatment decision for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infection. Advances in Therapy 2019 Sep;36(9):2475-86.
9. Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez FR, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8-weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. Journal of Hepatology 2020 Mar;72(3):441-9.
10. Lampertico P, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, Brown A, Persico M, Wick N, Porcalla A, Pangerl A, Crown E, Larsen L, Yu Y, Wedemeyer H. Real-world effectiveness and safety of glecaprevir/pibrentasvir for treatment of patients with chronic HCV-infection: a meta-analysis. Journal of Hepatology 2020 Jun;72(6):1112-21.
11. Drysdale K, Ntuli Y, Bestwick J, Gelson W, Agarwal K, Forton D, Mutimer D, Elsharkawy AM, Townley C, Mahomed F, Foster GR. English hepatitis C registry data show high response rates to directly acting anti-virals even if treatment is not compensated. Alimentary Pharmacology & Therapy 2020 Jul;52(1):168-81.
12. Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM, Solà R. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Journal of Hepatology 2004 May;40(5):823-30.
13. U.S. Food & Drug Administration. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines mavyret, zepatier, and vosevi in some patients with advanced liver disease. FDA Drug Safety Communications. 08-28-2019. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and Accessed 2021 Aug 05.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]